Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge)

M. MacKenzie, M. V. Peshwa, Theodore Wun, J. Wolf, J. Mason, V. Caggiano, C. Redfern, G. Strang, F. Valone

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Mylovenge (APC8020) is an immunotherapy product consisting of autologous dendritic cells pulsed with the patient's immunoglobulin idiotype, which is a tumorspecific antigen. We are performing a trial of Mylovenge for treatment of patients with myeloma that is progressive after standard therapy. We have treated 42 patients and data are available for all 42. There are three patient groups: Patients with progressive disease after standard dose chemotherapy with high tumor burden (group 1, 16 patients) or intermediate tumor burden (group 2, 12 patients) and patients with disease progression after autologous stem cell transplantation (group 3, 14 patients). The median number of prior chemotherapy regimens was 3 (range 1 - 6). 45% had received radiation therapy and 52% had elevated B2 microglobulin. The table provides other demographic information. Group Age M/F IgG/IgA M Protein ECOG 0/1 B2M 1 69 9/7 13β 3.3 9/7 3.2 2 69 8/4 8/4 2.1 6/6 2.0 3 59 9/5 10/4 3.5 8/6 3.7 Mylovenge was prepared and infused in weeks 0, 4, 8, and 24 (patients 1 - 31) or weeks 0, 2. 4, and 24 (patients 32 - 42). Treatment was well tolerated. There were five treatment-related adverse events ( 11.9% of patients; 3% of infusions): 2 headaches, 1 sore arm, and 2 dyspnea. Sixteen patients (38%) appeared to benefit from treatment. Fifteen of these were in groups 1 and 2 (15/28, 54%). Six patients had minor decreases in serum M protein and 10 had disease stabilization 35 weeks with 4 having stabilization 18 months. The median time to progression was: group 1: 37.8 weeks; group 2: 32.0 weeks; and group 3: 12.4 weeks. Treatment with Mylovenge is well tolerated and benefits 1β to 1/2 of heavily pre-treated patients who are resistant to standard therapy. We have extended this trial to include patients with stable, low tumor burden after autologous stem cell transplantation.

Original languageEnglish (US)
JournalBlood
Volume96
Issue number11 PART I
StatePublished - 2000

Fingerprint

Multiple Myeloma
Refractory materials
Immunotherapy
Dendritic Cells
Tumors
Chemotherapy
Stem cells
Immunoglobulin Idiotypes
Stabilization
Radiotherapy
Immunoglobulin A
Proteins
Immunoglobulin G
Antigens
Tumor Burden
Stem Cell Transplantation
Therapeutics
Drug Therapy
Dyspnea
Headache

ASJC Scopus subject areas

  • Hematology

Cite this

MacKenzie, M., Peshwa, M. V., Wun, T., Wolf, J., Mason, J., Caggiano, V., ... Valone, F. (2000). Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge). Blood, 96(11 PART I).

Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge). / MacKenzie, M.; Peshwa, M. V.; Wun, Theodore; Wolf, J.; Mason, J.; Caggiano, V.; Redfern, C.; Strang, G.; Valone, F.

In: Blood, Vol. 96, No. 11 PART I, 2000.

Research output: Contribution to journalArticle

MacKenzie, M, Peshwa, MV, Wun, T, Wolf, J, Mason, J, Caggiano, V, Redfern, C, Strang, G & Valone, F 2000, 'Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge)', Blood, vol. 96, no. 11 PART I.
MacKenzie M, Peshwa MV, Wun T, Wolf J, Mason J, Caggiano V et al. Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge). Blood. 2000;96(11 PART I).
MacKenzie, M. ; Peshwa, M. V. ; Wun, Theodore ; Wolf, J. ; Mason, J. ; Caggiano, V. ; Redfern, C. ; Strang, G. ; Valone, F. / Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge). In: Blood. 2000 ; Vol. 96, No. 11 PART I.
@article{315fab3731974ff2ab727e9b19550a8d,
title = "Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge)",
abstract = "Mylovenge (APC8020) is an immunotherapy product consisting of autologous dendritic cells pulsed with the patient's immunoglobulin idiotype, which is a tumorspecific antigen. We are performing a trial of Mylovenge for treatment of patients with myeloma that is progressive after standard therapy. We have treated 42 patients and data are available for all 42. There are three patient groups: Patients with progressive disease after standard dose chemotherapy with high tumor burden (group 1, 16 patients) or intermediate tumor burden (group 2, 12 patients) and patients with disease progression after autologous stem cell transplantation (group 3, 14 patients). The median number of prior chemotherapy regimens was 3 (range 1 - 6). 45{\%} had received radiation therapy and 52{\%} had elevated B2 microglobulin. The table provides other demographic information. Group Age M/F IgG/IgA M Protein ECOG 0/1 B2M 1 69 9/7 13β 3.3 9/7 3.2 2 69 8/4 8/4 2.1 6/6 2.0 3 59 9/5 10/4 3.5 8/6 3.7 Mylovenge was prepared and infused in weeks 0, 4, 8, and 24 (patients 1 - 31) or weeks 0, 2. 4, and 24 (patients 32 - 42). Treatment was well tolerated. There were five treatment-related adverse events ( 11.9{\%} of patients; 3{\%} of infusions): 2 headaches, 1 sore arm, and 2 dyspnea. Sixteen patients (38{\%}) appeared to benefit from treatment. Fifteen of these were in groups 1 and 2 (15/28, 54{\%}). Six patients had minor decreases in serum M protein and 10 had disease stabilization 35 weeks with 4 having stabilization 18 months. The median time to progression was: group 1: 37.8 weeks; group 2: 32.0 weeks; and group 3: 12.4 weeks. Treatment with Mylovenge is well tolerated and benefits 1β to 1/2 of heavily pre-treated patients who are resistant to standard therapy. We have extended this trial to include patients with stable, low tumor burden after autologous stem cell transplantation.",
author = "M. MacKenzie and Peshwa, {M. V.} and Theodore Wun and J. Wolf and J. Mason and V. Caggiano and C. Redfern and G. Strang and F. Valone",
year = "2000",
language = "English (US)",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART I",

}

TY - JOUR

T1 - Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge)

AU - MacKenzie, M.

AU - Peshwa, M. V.

AU - Wun, Theodore

AU - Wolf, J.

AU - Mason, J.

AU - Caggiano, V.

AU - Redfern, C.

AU - Strang, G.

AU - Valone, F.

PY - 2000

Y1 - 2000

N2 - Mylovenge (APC8020) is an immunotherapy product consisting of autologous dendritic cells pulsed with the patient's immunoglobulin idiotype, which is a tumorspecific antigen. We are performing a trial of Mylovenge for treatment of patients with myeloma that is progressive after standard therapy. We have treated 42 patients and data are available for all 42. There are three patient groups: Patients with progressive disease after standard dose chemotherapy with high tumor burden (group 1, 16 patients) or intermediate tumor burden (group 2, 12 patients) and patients with disease progression after autologous stem cell transplantation (group 3, 14 patients). The median number of prior chemotherapy regimens was 3 (range 1 - 6). 45% had received radiation therapy and 52% had elevated B2 microglobulin. The table provides other demographic information. Group Age M/F IgG/IgA M Protein ECOG 0/1 B2M 1 69 9/7 13β 3.3 9/7 3.2 2 69 8/4 8/4 2.1 6/6 2.0 3 59 9/5 10/4 3.5 8/6 3.7 Mylovenge was prepared and infused in weeks 0, 4, 8, and 24 (patients 1 - 31) or weeks 0, 2. 4, and 24 (patients 32 - 42). Treatment was well tolerated. There were five treatment-related adverse events ( 11.9% of patients; 3% of infusions): 2 headaches, 1 sore arm, and 2 dyspnea. Sixteen patients (38%) appeared to benefit from treatment. Fifteen of these were in groups 1 and 2 (15/28, 54%). Six patients had minor decreases in serum M protein and 10 had disease stabilization 35 weeks with 4 having stabilization 18 months. The median time to progression was: group 1: 37.8 weeks; group 2: 32.0 weeks; and group 3: 12.4 weeks. Treatment with Mylovenge is well tolerated and benefits 1β to 1/2 of heavily pre-treated patients who are resistant to standard therapy. We have extended this trial to include patients with stable, low tumor burden after autologous stem cell transplantation.

AB - Mylovenge (APC8020) is an immunotherapy product consisting of autologous dendritic cells pulsed with the patient's immunoglobulin idiotype, which is a tumorspecific antigen. We are performing a trial of Mylovenge for treatment of patients with myeloma that is progressive after standard therapy. We have treated 42 patients and data are available for all 42. There are three patient groups: Patients with progressive disease after standard dose chemotherapy with high tumor burden (group 1, 16 patients) or intermediate tumor burden (group 2, 12 patients) and patients with disease progression after autologous stem cell transplantation (group 3, 14 patients). The median number of prior chemotherapy regimens was 3 (range 1 - 6). 45% had received radiation therapy and 52% had elevated B2 microglobulin. The table provides other demographic information. Group Age M/F IgG/IgA M Protein ECOG 0/1 B2M 1 69 9/7 13β 3.3 9/7 3.2 2 69 8/4 8/4 2.1 6/6 2.0 3 59 9/5 10/4 3.5 8/6 3.7 Mylovenge was prepared and infused in weeks 0, 4, 8, and 24 (patients 1 - 31) or weeks 0, 2. 4, and 24 (patients 32 - 42). Treatment was well tolerated. There were five treatment-related adverse events ( 11.9% of patients; 3% of infusions): 2 headaches, 1 sore arm, and 2 dyspnea. Sixteen patients (38%) appeared to benefit from treatment. Fifteen of these were in groups 1 and 2 (15/28, 54%). Six patients had minor decreases in serum M protein and 10 had disease stabilization 35 weeks with 4 having stabilization 18 months. The median time to progression was: group 1: 37.8 weeks; group 2: 32.0 weeks; and group 3: 12.4 weeks. Treatment with Mylovenge is well tolerated and benefits 1β to 1/2 of heavily pre-treated patients who are resistant to standard therapy. We have extended this trial to include patients with stable, low tumor burden after autologous stem cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=33748656922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748656922&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748656922

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART I

ER -